Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Breast cancer has been a formidable health challenge ... The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin ...

Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for patients with stage 2 or 3 hormone receptor-positive, HER2-negative breast cancer reduced patients’ risk for ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Relay Therapeutics (RLAY – Research Report), retaining the price ...

NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

The Food and Drug Administration (FDA) has just approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor as treatment for people with HR+/HER2- stage II and III early breast ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

Six/UW/Seattle Children’s Cancer Consortium scientists received new funding from the Breast Cancer Research Foundation to ...